Anti-Tetrodotoxin polyclonal antibody (DPAB-DC4815)


Host Species
Antibody Isotype
Species Reactivity
Tetrodotoxin conjugated with carrier proteins.


Application Notes
ELISA: 1:2000-1:10000; IHC: 1:1000-1:5000; & The optimal working dilution should be determined by the end user.
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.


Alternative Names
TTX; Tetrodotoxin


Have you cited DPAB-DC4815 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling

We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Monitoring of electron bunch length by using Terahertz coherent transition radiation


Authors: Su, Xiaolu; Yan, Lixin; Du, Yingchao; Zhang, Zhen; Zhou, Zheng; Wang, Dong; Zheng, Lianmin; Tian, Qili; Huang, Wenhui; Tang, Chuanxiang

In this paper, ultrashort bunch length monitoring was demonstrated based on Terahertz (THz) coherent transition radiation (CTR) in Tsinghua Thomson scattering X-ray (TTX) source. The radiation produced by electron bunch is split into three paths: one of them is used to detect the total energy, while the other two paths are filtered with different THz band-pass filters before detection. The bunch length variation can be obtained by calculating the ratio between the filtered energy and the total energy. The bunch is compressed by a chicane and via changing the current of chicane, the ratio of filtered energy and total energy changed correspondingly. It is a simple supplemental approach to monitor the bunch length during beam conditioning and facility operation. Bunch arrival-time jitter and nonlinear effects in chicane are observed in the experiment during the measurement of filtered energy and total energy. (C) 2017 Elsevier B.V. All rights reserved.

Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival


Authors: Waechter, Sabine; Vorlaender, C.; Schabram, J.; Mintziras, I.; Fuelber, I.; Manoharan, J.; Holzer, K.; Bartsch, D. K.; Maurer, E.

Purpose The prognosis of anaplastic thyroid cancer (ATC) is poor. Despite various attempts to modify common treatment modalities, including surgery, external beam radiation (EBRT) and chemotherapy (CTX), no standardized treatment is yet established. This study aimed to analyze the changing trends of treatment concepts and associated overall survival (OS) over the last two decades. Methods A retrospective analysis was conducted on 42 patients with histologically confirmed ATC. The outcome measures included the evaluation of clinical characteristics and treatments performed with regard to OS. Results Median OS for all tumor stages was 6 (range 1 week-79) months, 6.5 months for stage IVA/B and 4 months for stage IVC carcinoma patients. Twenty-one patients with stage IVA/B carcinomas underwent curative treatment, including thyroidectomy with lymphadenectomy (TTX plus LAD, n = 11) or multimodal treatment with TTX plus LAD and EBRT plus/minus CTX (n = 10). The median OS of patients with stage IVA/B carcinomas was significantly prolonged after multimodal treatment than after surgery alone (25 vs. 3 months, p = 0.04). Fifteen of 18 patients with stage IVC carcinomas received palliative, 3 patients multimodal treatment. The median OS of stage IVC patients after trimodal therapy was not significantly longer than after debulking procedures (6 vs. 7 months, p = 0.25). In the time period 1999-2009, only 4 (21%) patients received multimodal treatment compared to 9 (39%) in the period from 2009 to 2019, but this did not result in a significantly prolonged survival in the latter period (8.5 vs. 15 months, p = 0.61). Conclusion Concurrent radio- and/or chemotherapy in combination with surgery seems to result in improved survival in stage IVA/B ATC, whereas this is not the case in patients with stage IVC tumors. Novel treatment regimens are urgently needed to improve the dismal prognosis of ATC.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket